- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01918124
A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer (EC-0701)
A Phase II Clinical Trial of Adjuvant Postoperative Irradiation Combined With Paclitaxel/Carboplatin(TP) or Cisplatin/Doxorubicin/Cyclophosphamide (CAP) Chemotherapy for Patients With High-risk Endometrial Cancer
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Shanghai Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have had a hysterectomy (total abdominal, vaginal hysterectomy, or laparoscopic-assisted vaginal hysterectomy) or modified radical hysterectomy or radical hysterectomy and bilateral salpingo-oophorectomy no more than 8 weeks prior to start of radiation therapy.
Additional surgical staging procedures are permissible but not required.
Risk factors: patients must fit one of the following:
- Pelvic lymph node metastases
- Paraaortic lymph node metastases
- Grade 3 with myometrial invasion >50%
- With stromal invasion of cervix
- Known extrauterine disease (excluding second primary) confined to the pelvis.
- High risk pathological type include: uterine papillary serous carcinoma, clear cell carcinoma, squamous cell carcinoma, undifferentiated carcinoma,
- No known gross residual disease, or distant metastases.
- Eastern Cooperative Oncology Group (ECOG) score<=2; Age 18~75.
- White Blood Cell (WBC)≥4000/mm3, granulocytes ≥1500/mcl, platelets≥100,000/mcl.
- Acceptable hepatic and renal function: creatinine <=1.4 mg%, bilirubin and serum glutamate oxaloacetate transaminase (SGOT) <=2*normal.
- No medical contraindications to chemotherapy, or radiation therapy.
- Study-specific signed informed consent.
Exclusion Criteria:
- Prior pelvic radiation therapy.
- Positive peritoneal cytology only for stage IIIa (FIGO 1998).
- With history of other malignancies less than 5 years.
- With gross residual disease, or distant metastases.
With endometrioid endometrial carcinoma and no risk factors:
- with myometrial invasion <50%
- Grade 1~2, with myometrial invasion >50%
- With serious internal diseases which affect designed treatment
- With psychotic disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: radiotherapy combined with chemotherapy
Arm Label: radiotherapy combined with chemotherapy: Radiotherapy: Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery. Cisplatin: Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy. Cisplatin and Doxorubicin and Cyclophosphamide: Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) given at 3 week intervals following completion of radiotherapy. Paclitaxel and Carboplatin: Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy. |
Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Free Survival(DFS)
Time Frame: From date of randomization until the date of first documented progression, assedded up to 60 months
|
From date of randomization until the date of first documented progression, assessed up to 60 months.
|
From date of randomization until the date of first documented progression, assedded up to 60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: From date of randomization until the date of death from any cause, assedded up to 60 months.
|
From date of randomization until the date of death from any cause, assessed up to 60 months.
|
From date of randomization until the date of death from any cause, assedded up to 60 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse events and number of patients completed the treatments
Time Frame: up to 5 years
|
Number of patients completed the treatment and number of patients with adverse events up to 5 years.
|
up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Huaying Wang, Doctor, Shanghai Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Postoperative Complications
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Endometrial Neoplasms
- Prosthesis Failure
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Carboplatin
- Paclitaxel
- Cisplatin
- Doxorubicin
Other Study ID Numbers
- 070148-7
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prosthesis Survival
-
Technical University of MunichUnknown
-
Cukurova UniversityCompletedSurvival, Prosthesis | Clinical Acceptability, ProsthesisTurkey
-
Cairo UniversityNot yet recruiting
-
Cairo UniversityUnknown
-
Medacta International SARecruiting
-
Susanne ScherrerITI FoundationCompleted
-
Malo ClinicInvibio LtdEnrolling by invitation
-
Malo ClinicInvibio LtdEnrolling by invitationProsthesis SurvivalPortugal
-
Malo ClinicInvibio LtdActive, not recruiting
-
Istituto Ortopedico RizzoliCompleted
Clinical Trials on radiotherapy
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
University Hospital OstravaRecruiting
-
UNICANCERNational Cancer Institute, FranceRecruitingBreast Cancer | DCIS | Low Risk DCIS | Breast Conserving Surgery | Radiotherapy OmissionFrance
-
University Medical Center GroningenCatharina Ziekenhuis Eindhoven; Academisch Medisch Centrum - Universiteit van... and other collaboratorsActive, not recruiting
-
Fudan UniversityZhejiang Cancer Hospital; Huashan Hospital; Henan Cancer Hospital; Hunan Cancer... and other collaboratorsNot yet recruiting
-
The Netherlands Cancer InstituteLeiden University Medical CenterRecruitingSoft Tissue SarcomasNetherlands
-
Radboud University Medical CenterKoningin Wilhelmina Fonds; Maastro Clinic, The NetherlandsTerminatedSpinal MetastasesNetherlands
-
National University Hospital, SingaporeTan Tock Seng HospitalUnknownGastric CancerSingapore
-
Mediterranean Institute of OncologyUniversity of Palermo; University of MessinaRecruitingQuality of Life | Neurocognitive Deficit | Activities of Daily LivingItaly